Alena Savanevich1, Olgierd Ashuryk2, Cezary Cybulski2, Jan Lubiński2, Jacek Gronwald3. 1. Department of Obstetrics and Gynecology, Grodno State Medical University, Grodno, Belarus. 2. International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland. 3. International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland. jgron@pum.edu.pl.
Abstract
BACKGROUND: Mutations in BRCA1 and BRCA2 are well-established risk factors for breast and ovarian cancer. In Central-Eastern European counties, the founder mutations in the BRCA1 are responsible for a significant proportion of ovarian cancer cases, however, regional differences in the frequencies of various mutations may exist. The spectrum and frequency of BRCA1/2 mutations between ovarian cancer patients have not yet been precisely established in Belarus. METHODS: Two hundred fourteen consecutive unselected cases of ovarian cancer patients from the region of West Belarus were examined. We studied 13 founder mutations in BRCA1 (c.5266dupC, c.4035delA, c.5251C > T, c.181 T > G, c.676delT, c.68_69delAG, c.3700_3704delGTAAA, c.1687C > T, c.3756_3759delGTCT) and in BRCA2 (c.658_659delGT, c.7913_7917delTTCCT, c.3847_3848delGT, c.5946delT) characteristic for Central European population. RESULTS: A BRCA1 or BRCA2 founder mutations were detected in 54 of the 214 (25.2%) ovarian cancer cases. The BRCA1 c.5266dupC mutation was detected in 28 patients, followed by c.4035delA mutation observed in 18 patients. BRCA1 c.3756_3759delGTCT, c.68_69delAG, and c.1687C > T were found in 3, 2, and 1 women, respectively. BRCA2 c.658_659delGT mutation was detected in 2 ovarian cancer patients. The median age of diagnosis of the 54 hereditary ovarian cancers was 57.5 years. CONCLUSIONS: The frequency of 13 causative BRCA1 and BRCA2 founder mutations in West Belarus was higher than in other Slavic countries. Testing of BRCA1 (c.5266dupC, c.4035delA, c.3756_3759delGTCT, c.68_69delAG, c.1687C > T as well as c.181 T > G) and BRCA2 (c.658_659delGT) mutations should be considered an inexpensive and sensitive test panel for this population.
BACKGROUND: Mutations in BRCA1 and BRCA2 are well-established risk factors for breast and ovarian cancer. In Central-Eastern European counties, the founder mutations in the BRCA1 are responsible for a significant proportion of ovarian cancer cases, however, regional differences in the frequencies of various mutations may exist. The spectrum and frequency of BRCA1/2 mutations between ovarian cancerpatients have not yet been precisely established in Belarus. METHODS: Two hundred fourteen consecutive unselected cases of ovarian cancerpatients from the region of West Belarus were examined. We studied 13 founder mutations in BRCA1 (c.5266dupC, c.4035delA, c.5251C > T, c.181 T > G, c.676delT, c.68_69delAG, c.3700_3704delGTAAA, c.1687C > T, c.3756_3759delGTCT) and in BRCA2 (c.658_659delGT, c.7913_7917delTTCCT, c.3847_3848delGT, c.5946delT) characteristic for Central European population. RESULTS: A BRCA1 or BRCA2 founder mutations were detected in 54 of the 214 (25.2%) ovarian cancer cases. The BRCA1c.5266dupC mutation was detected in 28 patients, followed by c.4035delA mutation observed in 18 patients. BRCA1c.3756_3759delGTCT, c.68_69delAG, and c.1687C > T were found in 3, 2, and 1 women, respectively. BRCA2c.658_659delGT mutation was detected in 2 ovarian cancerpatients. The median age of diagnosis of the 54 hereditary ovarian cancers was 57.5 years. CONCLUSIONS: The frequency of 13 causative BRCA1 and BRCA2 founder mutations in West Belarus was higher than in other Slavic countries. Testing of BRCA1 (c.5266dupC, c.4035delA, c.3756_3759delGTCT, c.68_69delAG, c.1687C > T as well as c.181 T > G) and BRCA2 (c.658_659delGT) mutations should be considered an inexpensive and sensitive test panel for this population.
Entities:
Keywords:
BRCA1 and BRCA2 mutation; Belarus; Epithelial ovarian cancer; Mutation
Authors: P Elsakov; J Kurtinaitis; S Petraitis; V Ostapenko; M Razumas; T Razumas; R Meskauskas; K Petrulis; A Luksite; J Lubiński; B Górski; S A Narod; J Gronwald Journal: Clin Genet Date: 2010-10 Impact factor: 4.438
Authors: Anna P Sokolenko; Natalia V Mitiushkina; Konstantin G Buslov; Elena M Bit-Sava; Aglaya G Iyevleva; Elena V Chekmariova; Ekatherina Sh Kuligina; Yulia M Ulibina; Maxim E Rozanov; Evgeny N Suspitsin; Dmitry E Matsko; Oleg L Chagunava; Dmitry Yu Trofimov; Peter Devilee; Cees Cornelisse; Alexandr V Togo; Vladimir F Semiglazov; Evgeny N Imyanitov Journal: Eur J Cancer Date: 2006-06-05 Impact factor: 9.162
Authors: J P Struewing; P Hartge; S Wacholder; S M Baker; M Berlin; M McAdams; M M Timmerman; L C Brody; M A Tucker Journal: N Engl J Med Date: 1997-05-15 Impact factor: 91.245
Authors: E Levy-Lahad; R Catane; S Eisenberg; B Kaufman; G Hornreich; E Lishinsky; M Shohat; B L Weber; U Beller; A Lahad; D Halle Journal: Am J Hum Genet Date: 1997-05 Impact factor: 11.025
Authors: Anna P Sokolenko; Tatiana N Sokolova; Valeria I Ni; Elena V Preobrazhenskaya; Aglaya G Iyevleva; Svetlana N Aleksakhina; Alexandr A Romanko; Alexandr A Bessonov; Tatiana V Gorodnova; Elena I Anisimova; Elena L Savonevich; Ilya V Bizin; Ilya A Stepanov; Petr V Krivorotko; Igor V Berlev; Alexey M Belyaev; Alexandr V Togo; Evgeny N Imyanitov Journal: Breast Cancer Res Treat Date: 2020-08-09 Impact factor: 4.872
Authors: Tomasz Kluz; Andrzej Jasiewicz; Elżbieta Marczyk; Robert Jach; Anna Jakubowska; Jan Lubiński; Steven A Narod; Jacek Gronwald Journal: Hered Cancer Clin Pract Date: 2018-02-27 Impact factor: 2.857
Authors: Mateja Krajc; Erik Teugels; Janez Zgajnar; Guido Goelen; Nikola Besic; Srdjan Novakovic; Marko Hocevar; Jacques De Grève Journal: BMC Med Genet Date: 2008-09-10 Impact factor: 2.103
Authors: Alena Savanevich; Oleg Oszurek; Jan Lubiński; Cezary Cybulski; Tadeusz Dębniak; Steven A Narod; Jacek Gronwald Journal: Fam Cancer Date: 2014-09 Impact factor: 2.375
Authors: G A Yanus; E L Savonevich; A P Sokolenko; A A Romanko; V I Ni; E Kh Bakaeva; O A Gorustovich; I V Bizin; E N Imyanitov Journal: Fam Cancer Date: 2022-05-21 Impact factor: 2.375